Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life-changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a…More valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.
Oxford Biomedica does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Shipping Information
Please fill out the form below and click "Place Order" to complete your order.